The role of pathologists in the era of personalized medicine

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 4, 2009, Pages 605-610

  Walk, Eric E ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

CANCER PATIENT; CLINICAL EDUCATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; CONFERENCE PAPER; DIAGNOSTIC TEST; DRUG RESEARCH; EQUIPMENT; GENE AMPLIFICATION; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; PATHOLOGIST; PATIENT CARE; PATIENT SELECTION; PERSONALIZED MEDICINE; PHYSICIAN ATTITUDE; PROGNOSIS; TREATMENT OUTCOME;

HUMANS; PATHOLOGY; PHYSICIANS;

EID: 64849083705     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. 2001;7(5):201-204.
2. US Food and Drug Administration. Challenge and opportunity on the critical path to new medical products. FDA Web site. http://www.fda.gov/oc/ initiatives/ criticalpath/whitepaper.html. Accessed July 14, 2008.
3. US Food and Drug Administration. Drug-diagnostic co-development concept paper (draft). FDA Web site. http://www.fda.gov/cder/genomics/pharmacoconceptfn. pdf. Accessed July 13, 2008.
4. Allison M. Is personalized medicine finally arriving? Nature Biotechnol. 2008;26(5):509-517.
5. Giordano TJ. Molecular profiling and personalized predictive pathology: challenge to the academic surgical pathology community. Am J Surg Pathol. 2006;30(3):402-404.
6. Allred DC, WuY, Mao S, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Can Res. 2008;14(2):370-378.
7. Shipitsin M, Campbell LL, Argani P, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007;11(2):259-273.
8. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-6837.
9. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a southwest oncology group study. J Clin Oncol. 2005; 23(28):6838-6845.
10. Tsao MS. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med. 2005;353(2):133-144.
11. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352(8):786-792.
12. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Can Res. 2006;12(21): 6494-6501.
13. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008;105(6):2070-2075.
14. Engelman JA, Zejhullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039-1042.
15. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 2007;104(52):20932- 20937.
16. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest. 2008;118(7):2609-2619.
17. Navarro AA, Gaya A, Martinez A, et al. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood. 2008;111(5):2825-2832.
18. Strobel SL, Tatchell T. The surgical pathology report as an educational tool for cancer patients. Ann Clin Lab Sci. 2002;32(4):363-368.
19. Strobel SL. A role for pathologists and registrars in the education of patients with prostate cancer. J Regist Manage. 2002;29(1):15-17.
20. Baron S. FAQ. Executive physician FAQ. Executive physician Web site. http://www.executivephysician.com/3.html. AccessedJuly 13, 2008.